Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.32%77 Earnings per Share (Diluted) is $0.15 as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Coloplast AS ranks worse than 63.64% on this metric.
Coloplast AS's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.07.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.15.
Coloplast AS's EPS without NRI for the
three
months ended in Mar. 2026 was $0.10.
Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.37.
During the past 12 months, Coloplast AS's average EPS without NRIGrowth Rate was 15.10% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -1.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 1.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 4.10% per year.
During the past 13 years, Coloplast AS's highest 3-Year average EPS without NRI Growth Rate was 56.10% per year. The lowest was -9.80% per year. And the median was 6.60% per year.
Coloplast AS (OTCPK:CLPBY) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Coloplast AS Earnings per Share (Diluted) Related Terms
Coloplast AS Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's PE Ratio distribution charts can be found below:
* The bar in red indicates where Coloplast AS's PE Ratio falls into.
Coloplast AS Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Coloplast AS's Earnings Per Share (Diluted) for the fiscal year that ended in Sep. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.15 mean?
Coloplast AS (CLPBY) has a Earnings per Share (Diluted) of $0.15 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #420 out of 660 companies in the Medical Devices & Instruments industry, placing it in the top 63.6%.
Is Coloplast AS's Earnings per Share (Diluted) too high?
Coloplast AS's current Earnings per Share (Diluted) is $0.15. The Medical Devices & Instruments industry median Earnings per Share (Diluted) is 8.15. Coloplast AS's value of $0.15 is 98.2% below this industry median. Based on the distribution chart, Coloplast AS ranks #420 out of 660 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Earnings per Share (Diluted) compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #420 out of 660 companies for Earnings per Share (Diluted). This places Coloplast AS in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.15. Coloplast AS's value of $0.15 is 98.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.15, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Earnings per Share (Diluted) of $0.15 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Earnings per Share (Diluted) is $0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.71 — trading 48.6% below its estimated fair value. The current Earnings per Share (Diluted) is $0.15 and 98.2% below the Medical Devices & Instruments industry median of 8.15. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Earnings per Share (Diluted) is $0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.71 is trading 48.6% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Earnings per Share (Diluted): $0.15
GF Value™: $13.05 vs. price of $6.71 (48.6% below fair value)
Industry Position: 98.2% below the Medical Devices & Instruments median (#420 of 660)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
